Back

Modelling APOL1-mediated kidney inflammation and fibrosis using a partially reprogrammed urine derived SIX2-positive renal progenitor cell line.

Thimm, C.; Mack, R.; Adjei-Aruna, O.; Wruck, W.; Adjaye, J.

2025-07-29 molecular biology
10.1101/2025.07.28.667124 bioRxiv
Show abstract

BackgroundCKD affects approximately 850 million people worldwide and is a leading cause of mortality. Podocytes, cells in the kidney are terminally differentiated and incapable of division in vivo making the establishment of primary cultures particularly challenging. The ability of cells to proliferate and avoid senescence is closely linked to telomere length. When telomere length becomes critically reduced, it results in cellular senescence. MethodsWe present the successful rejuvenation of a human SIX2-positive renal progenitor cell line derived from the urine of a 30-year-old West African male (UM30-OSN). To achieve partial reprogramming, plasmids expressing the Yamanaka factors OCT4, SOX2, NANOG, c-Myc, and KLF4 were employed. ResultsUM30-OSN expresses the pluripotency-associated marker SSEA4, renal stem cell markers such as SIX2, CD133 and CD24, determined by immunofluorescence, FACS and qPCR. Expression analysis revealed downregulation of senescence markers p21and p53 and upregulation of proliferation-associated genes PCNA, KI67 and TERT, confirming rejuvenation. Upon podocyte differentiation, UM30-OSN cells expressed podocyte-specific markers NPHS1, NPHS2, SYNPO and CD2AP. Comparative transcriptome analyses revealed a correlation co-efficiency (R2 = 0.88) with the immortal podocyte line AB 8/13. To demonstrate the usefulness of UM30-OSN to model APOL1-mediated kidney disease, we investigated the effects of Interferon-{gamma} (IFN-{gamma}) on UM30-OSN derived podocytes and evaluated the potential of the JAK1/JAK2 inhibitor Baricitinib to mitigate IFN-{gamma}-induced cellular responses. IFN-{gamma} stimulation resulting in increased phosphorylation of STAT1, activation of APOL1, upregulation of pro-inflammatory and fibrotic markers such as, IL-6, TGF-{beta}, Vimentin, Fibronectin, and morphological changes indicative of cell stress. Pre-treatment with Baricitinib effectively inhibited STAT1 phosphorylation, reduced expression of pro-inflammatory and fibrosis-associated genes, and preserved podocyte morphology. ConclusionGiven their robust proliferation capacity, UM30-OSN cells represent a valuable additional model for investigating kidney-associated diseases such the contribution of APOL1 high-risk variants to kidney injury and fibrosis.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3612 papers in training set
Top 3%
11.3%
2
Kidney International
29 papers in training set
Top 0.1%
8.1%
3
Cells
249 papers in training set
Top 0.1%
6.9%
4
International Journal of Molecular Sciences
494 papers in training set
Top 1%
5.7%
5
PLOS ONE
5266 papers in training set
Top 32%
4.4%
6
Molecular Medicine
11 papers in training set
Top 0.1%
4.1%
7
Journal of the American Society of Nephrology
56 papers in training set
Top 0.3%
3.3%
8
Human Molecular Genetics
141 papers in training set
Top 0.9%
2.5%
9
Stem Cell Research & Therapy
30 papers in training set
Top 0.3%
2.2%
10
Communications Biology
993 papers in training set
Top 10%
2.2%
50% of probability mass above
11
The FASEB Journal
194 papers in training set
Top 2%
2.2%
12
Frontiers in Immunology
638 papers in training set
Top 6%
1.8%
13
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.3%
1.8%
14
Journal of Personalized Medicine
28 papers in training set
Top 0.4%
1.8%
15
Nature Communications
5641 papers in training set
Top 44%
1.8%
16
eLife
5828 papers in training set
Top 48%
1.7%
17
Journal of Cellular and Molecular Medicine
20 papers in training set
Top 0.3%
1.4%
18
iScience
1154 papers in training set
Top 22%
1.4%
19
Cell Death Discovery
58 papers in training set
Top 0.8%
1.2%
20
Cancers
213 papers in training set
Top 4%
1.1%
21
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 2%
1.1%
22
BMC Nephrology
18 papers in training set
Top 0.3%
1.0%
23
Cell Death & Disease
126 papers in training set
Top 3%
0.9%
24
Experimental & Molecular Medicine
14 papers in training set
Top 0.1%
0.9%
25
JCI Insight
277 papers in training set
Top 7%
0.9%
26
Biomolecules
100 papers in training set
Top 3%
0.9%
27
Journal of Translational Medicine
57 papers in training set
Top 2%
0.9%
28
Advanced Science
286 papers in training set
Top 9%
0.9%
29
Biology
45 papers in training set
Top 0.8%
0.9%
30
American Journal of Physiology-Renal Physiology
28 papers in training set
Top 0.4%
0.9%